HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$3.67
Price-0.81%
-$0.03
$7.896m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$832.840k
-
1y CAGR-
3y CAGR-
5y CAGR-$21.554m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.13
-
1y CAGR-
3y CAGR-
5y CAGR-$51.970k
$28.910m
Assets$28.962m
Liabilities$6.421m
Debt22.2%
-0.6x
Debt to EBITDA-$12.708m
-
1y CAGR-
3y CAGR-
5y CAGR